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Introduction
Liver cancer is the fifth most prevalent neoplasm
worldwide but the second most common cause of
cancer-related mortality in men (1). In women, it is
the seventh most common cancer but the sixth lead-
ing cause of cancer-related death (1). This is in part
because of the poor prognosis for many patients,
more than 70% of whom present with advanced dis-
ease (2,3). The highest incidence of liver cancer is
found in East and South-East Asia and in middle
and West Africa (1). Although the incidence rate in
more developed regions of the world is lower,
including central Europe and the USA, liver cancer
incidence rates in the developed world are increasing
(1). The global incidence of hepatocellular carcinoma
(HCC) is predicted to continue to increase until a
plateau is reached in 2015–2020 (2). Risk factors for
the development of HCC include hepatitis B viral
(HBV) and hepatitis C viral (HCV) infection, high
alcohol intake, obesity and diabetes (1,4).
HCC treatments have developed rapidly over the
last two decades in parallel with significant develop-
ments in diagnosis, surveillance, staging system and
tumour assessment criteria. However, the majority of
patients present with unresectable HCC (uHCC).
Current non-surgical treatment options include loco-
regional treatment (LRT), for example transarterial
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Aims: Global Investigation of therapeutic DEcisions in hepatocellular carcinoma
and Of its treatment with sorafeNib (GIDEON), a global, non-interventional, surveil-
lance study, aims to evaluate the safety of sorafenib in all patients with unresec-
table hepatocellular carcinoma (uHCC) under real-life practice conditions,
particularly Child-Pugh B patients, who were not well represented in clinical trials.
Methods: Treatment decisions are determined by each physician according to
local prescribing guidelines and clinical practice. Patients with uHCC who are can-
didates for systemic therapy, and for whom a decision has been made to treat
with sorafenib, are eligible for inclusion. Demographic data and medical and dis-
ease history are recorded at entry. Sorafenib dosing and adverse events (AEs) are
collected throughout the study. Results: From January 2009 to April 2011, >3000
patients from 39 countries were enrolled. The prespecified first interim analysis
was conducted when the initial approximately 500 treated patients had been fol-
lowed up for ‡4 months; 479 were valid for safety evaluation. Preplanned sub-
group analyses indicate differences in patient characteristics, disease aetiology and
previous treatments by region. Variation in sorafenib dosing by specialty are also
observed; Child-Pugh status did not appear to influence the starting dose of
sorafenib. The type and incidence of AEs was consistent with findings from previ-
ous clinical studies. AE profiles were comparable between Child-Pugh subgroups.
Discussion: The GIDEON study is generating a large, robust database from a
broad population of patients with uHCC. First interim analyses have shown global
and regional differences in patient characteristics, disease aetiology and practice
patterns. Subsequent planned analyses will allow further evaluation of early trends.
What’s known
• Currently, there is no global consensus on the
management of patients with uHCC. A worldwide
study of regional uHCC treatment practices is
therefore needed to advance the management of
uHCC
• The oral multikinase inhibitor sorafenib is the
only systemic therapy indicated for the treatment
of uHCC, but data from Child-Pugh B patients
are limited
What’s new
• The non-interventional GIDEON study is
evaluating sorafenib in uHCC under real-life
clinical practice conditions and therefore includes
a broader patient demographic than that
represented in controlled clinical trials
• GIDEON allows global variations in uHCC
management to be evaluated in a single robust
study, and the prespecified first interim analysis
results highlight differences in patient and
disease characteristics, aetiology, and risk factors
for uHCC, and sorafenib dosing, by region and
physician specialty
• The type and incidence of AEs is as expected and
appears to be similar in Child-Pugh A and B patients
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chemoembolisation (TACE) and ablation therapy,
although it is recognised that these have maximal
effect for smaller tumours without vascular invasion
(5–8).
Two placebo-controlled Phase III studies (SHARP
and Asia-Pacific) have demonstrated that the oral
multikinase inhibitor sorafenib (Nexavar; Bayer
HealthCare Pharmaceuticals, Berlin, Germany; Onyx
Pharmaceuticals, San Francisco, CA) significantly
improves overall survival in patients with uHCC
(9,10). Sorafenib is the first systemic anticancer agent
to be indicated for patients with uHCC and is cur-
rently recommended for selected patients with Child-
Pugh A or B liver function and unresectable disease
who are unsuitable for liver transplantation (5,8).
Sorafenib is also indicated in patients with local dis-
ease unsuitable for surgery because of performance
status or comorbidity, and for patients with meta-
static disease (5).
The Global Investigation of therapeutic DEcisions
in HCC and Of its treatment with sorafeNib (GID-
EON) study is the largest prospective, non-interven-
tional study undertaken in patients with uHCC. The
study was initiated to fulfil the post-approval com-
mitment to licensing agencies to gather more com-
prehensive data on the use of sorafenib in patients
with Child-Pugh B liver function, who were excluded
from the randomised clinical trials, resulting in lim-
ited data for patients with more severe liver dysfunc-
tion (11). The primary objective of GIDEON is to
evaluate the safety of sorafenib in uHCC patients
under real-life clinical practice conditions (12).
Importantly, the GIDEON study is inclusive of the
diverse HCC population from 39 countries, thus
allowing both global and regional evaluation of prog-
nostic and predictive factors.
The robust database provided by GIDEON on
treatment patterns and outcomes for uHCC patients
who are candidates for systemic therapy is a unique
resource to further study multiple patient subgroups
and physicians’ practice patterns around the world.
Thus, the GIDEON study can generate data that
could better inform treatment choices and ultimately
improve outcomes for patients with uHCC. Results
from the first interim analysis are presented in this
paper.
Methods
Study design and objectives
GIDEON is a global, non-interventional, surveil-
lance study in which assignment to a particular
therapy is not mandated by a study protocol but
is decided by the participating physician, as previ-
ously described (13). The primary objective is to
evaluate the safety of sorafenib in patients with
uHCC who are candidates for systemic therapy
and in whom a decision to treat with sorafenib
has been made in real-life practice conditions. The
secondary objectives include efficacy and duration
of therapy with sorafenib. Objectives will be evalu-
ated in a variety of patient subsets, both globally
and across regions.
The first patient entered the study in 2009 and the
last patient was enrolled in April 2011, 20 months
before the anticipated date. Two preplanned interim
analyses were defined based on prespecified numbers
of patients who are treated with sorafenib and fol-
lowed for at least 4 months, the first interim at 500
patients and the second interim at 1500 patients. The
final analysis is planned 12 months after enrolment
of the 3000th treated patient (12).
The study is being conducted according to estab-
lished regulations and recommendations relating to
the conduct of a non-interventional study, according
to Good Clinical Practice where applicable to a non-
interventional study, and according to relevant local
laws, regulations and organisations, with documented
approval from appropriate ethics committee(s) ⁄ insti-
tutional review board as required (12).
Patients
Eligible patients must have histologically, cytologi-
cally or radiographically diagnosed uHCC and a life
expectancy of >8 weeks. They must also have pro-
vided signed, informed consent, and the local physi-
cian must have decided to treat them with sorafenib.
Radiographic diagnosis is based on findings from
multidimensional dynamic computed tomography
(CT), CT hepatic arteriography ⁄CT arterial portogra-
phy, or magnetic resonance imaging. Patient exclu-
sion criteria are based on the approved local product
information for sorafenib (12). Patients who received
at least one dose of sorafenib and underwent at least
one follow-up assessment after start of treatment are
evaluable for safety.
Data collection
All data are collected using case report forms, as pre-
viously described (12). Dosage details and duration
of sorafenib treatment are determined for each
patient, and data for discontinuation are summar-
ised. Adverse events (AEs) and serious AEs (SAEs)
are graded according to the Common Terminology
Criteria for Adverse Events version 3.0; other safety
variables are summarised descriptively.
Statistical methods
Based on previously conducted large, global, multi-
centre sorafenib studies for HCC, overall incidence
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rates of approximately 1–2% had been observed for
AEs of interest for further safety monitoring.
Approximately 3000 treated patients will provide an
84% chance of observing an AE, with a true inci-
dence of 1% in at least 25 patients. An overall sam-
ple size of 3000 patients was therefore considered
sufficient for evaluation of safety of both the overall
population and specific subgroups (12). All baseline
and safety data are summarised using descriptive
statistics. Preplanned subgroup analyses of safety
data were performed, stratified by region and physi-
cian specialty for multiple data points, such as
patient demographics and treatment history.
Results
Patients
Per protocol, the first planned interim analysis was
initiated when the initial approximately 500 treated
patients had been followed for at least 4 months.
Based on these criteria, the cut-off date used for the
first interim analysis was 11 April 2010. A total of
511 patients have been enrolled from 140 sites.
Patients have been enrolled from 39 countries across
five regions: Europe, Latin America, the USA, Japan
and Asia-Pacific (Figure 1). Of these, 479 were evalu-
able for safety analyses. Thirty-two patients were
excluded from the safety analyses, as they did not
receive sorafenib treatment or received sorafenib but
had no post-baseline evaluation.
Patient characteristics at baseline
Demographics and baseline characteristics for
patients evaluable for safety analyses are presented by
region and by leading physician specialty in Table 1.
Based on this first interim analysis, Asia-Pacific
countries enrolled the most patients. The distribution
of males ⁄ females was generally similar across
geographic regions, except for Latin America.
Patients in Asia-Pacific were relatively younger than
those in other regions.
Primary physician specialty
Overall, hepatologists ⁄ gastroenterologists (Hep ⁄GIs)
were the most common treating physicians (52%)
for patients with uHCC. Medical oncologists (Med
Oncs) treated 35% of patients across all regions.
Other treating specialties were less commonly
reported: surgery (7%), traditional Chinese medicine
(2%), radiology (1%) and anaesthesiology (1%).
Baseline characteristics were generally similar
between patients treated by Hep ⁄GIs and those trea-
ted by Med Oncs.
Prior locoregional treatment
Overall, 55% of patients received prior LRT
(Table 1). TACE was the most commonly received
LRT, with 44% of all patients receiving prior TACE
compared with only 15%, 5% and 3% of patients
receiving prior radiofrequency ablation, hepatic arte-
rial infusion and percutaneous ethanol injection,
respectively.
Prior locoregional treatment by region
Wide regional variation was observed in the use of
prior LRT. In Japan all patients received LRT prior
to sorafenib treatment; however, in Asia-Pacific, the
USA and Europe, 68%, 46% and 45% of patients
received prior LRT, respectively. TACE was the most
commonly received LRT in each region, although
with considerable regional variation. Prior TACE
treatment was more frequent in Japan (90%) and
Asia-Pacific (62%) and less common in Europe
(27%) and Latin America (22%).
Disease characteristics at study entry
Disease characteristics at study entry (defined as start
of sorafenib therapy, indicated by the initial visit) are
provided in Table 2. Patients were enrolled across all
Barcelona Clinic Liver Cancer (BCLC) stages. The
majority of patients (53%) had BCLC stage C; how-
ever, 19% of patients had BCLC stage B, and 10%
and 6% had stage A and D, respectively. More
143 patients
Latin America
3 countries
32 patients
USA
116 patients
Europe
11 countries
Japan
21 patients
Asia-Pacific
5 countries
167 patients
Figure 1 Distribution of patients included in the first interim analysis, by region
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patients had tumour, node, metastasis (TNM) stage
III and IV disease (37% and 35%, respectively) than
stage I (6%) or II (14%).
As might be anticipated, the majority of patients
in the overall population had Child-Pugh A status
(n = 278; 58%) and there were fewer Child-Pugh B
patients (n = 134; 28%). Subgroup analyses of dis-
ease characteristics at study entry suggest differ-
ences in many prognostic and predictive factors
across regions and by treating-physician specialty
(Table 2).
Disease characteristics by region
Some regional variation was observed: patients in
Asia-Pacific tended to have more advanced HCC
based on BCLC and TNM status at study entry than
in other regions (Table 2). In Asia-Pacific, 74% of
patients had BCLC stage C disease and 50% had
TNM stage IV disease compared with 24–51% and
13–43%, respectively, across other regions. Extrahe-
patic spread was also observed within considerably
more patients in Asia-Pacific (60%) than in other
regions (16–34%).
There was some regional variation observed in
Child-Pugh status (Table 2). A higher percentage of
patients (60–76%) in Asia-Pacific, Europe and Japan
had less advanced liver disease (i.e. Child-Pugh A)
than in either the USA (41%) or Latin America
(44%).
Differences in the aetiology of underlying liver dis-
ease were observed across regions (Table 2). The
majority of patients in Asia-Pacific had HBV infec-
tion (84%), whereas HCV infection was more com-
mon in Europe (33%) and the USA (50%). A greater
proportion of patients in Europe (42%) and the USA
(34%) had alcoholic liver disease compared with
other regions (16–19%). Thus, the major aetiologies
for uHCC were HCV and alcoholic liver disease in
Europe and the USA and HBV in Asia-Pacific.
Disease characteristics by physician specialty
Based on subgroup analyses by leading physician spe-
cialty, variations in disease characteristics were also
seen between patients principally treated by Med
Oncs and those treated by Hep ⁄GIs (Table 2). Med
Oncs tended to treat a greater number of patients
with advanced HCC (64% of patients had BCLC
stage C or D; 46% of patients had TNM stage IV)
compared with Hep ⁄GIs (59% of patients had BCLC
stage C or D; 28% of patients had TNM stage IV).
Hep ⁄GIs treated more patients with Child-Pugh B
status compared with Med Oncs (32% and 20%,
respectively).
Sorafenib administration
Sorafenib administration data from the overall popu-
lation are presented in Table 3. Overall, 76% of
patients received the approved initial daily dose of
Table 1 Demographic and baseline characteristics
Total
Geographic regions Specialty*
Asia-Pacific Europe USA Latin America Japan Hep ⁄GI Med Onc
Patients, n (% of total) 479 (100) 167 (35) 143 (30) 116 (24) 32 (7) 21 (4) 248 (52) 168 (35)
Median age, years 62 54 68 62 65 70 60 ⁄ 67 61
Gender, n (%)
Male 392 (82) 144 (86) 125 (87) 89 (77) 15 (47) 19 (90) 210 (85) 134 (80)
Female 87 (18) 23 (14) 18 (13) 27 (23) 17 (53) 2 (10) 38 (15) 34 (20)
ECOG PS, n (%),§
0 181 (38) 51 (31) 69 (48) 41 (35) 5 (16) 15 (71) 114 (46) 40 (24)
1 199 (42) 78 (47) 50 (35) 43 (37) 22 (69) 6 (29) 93 (38) 75 (45)
‡2 62 (13) 14 (8) 22 (15) 22 (19) 4 (12) 0 36 (15) 23 (14)
Prior LRT, n (%)– 264 (55) 114 (68) 64 (45) 53 (46) 12 (38) 21 (100) 132 (53) 88 (52)
Prior TACE, n (%) 212 (44) 104 (62) 39 (27) 43 (37) 7 (22) 19 (90) 107 (43) 68 (40)
Prior RFA, n (%) 72 (15) 17 (10) 35 (25) 8 (7) 6 (19) 6 (29) 45 (18) 20 (12)
Prior HAI, n (%) 26 (5) 14 (8) 2 (1) 6 (5) 2 (6) 2 (10) 17 (7) 4 (2)
Prior PEI, n (%) 15 (3) 4 (2) 8 (6) 0 0 3 (14) 12 (5) 2 (1)
*Other specialties not tabulated included surgery (n = 35), radiology (n = 6), anaesthesiology (n = 4) and traditional Chinese medicine (n = 10); Hep ⁄GI popula-
tion comprised 178 patients treated by hepatologists and 70 patients treated by gastroenterologists; Recorded at study entry (which is defined as start of therapy
and is indicated by the initial visit); §Data missing for 37 patients; –Data missing for one patient.
ECOG PS, Eastern Cooperative Oncology Group performance status; GI, gastroenterologist; HAI, hepatic arterial infusion; Hep, hepatologist; LRT, locoregional treat-
ment; Med Onc, medical oncologist; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; TACE, transarterial chemoembolisation.
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800 mg sorafenib, while 24% of patients received an
initial daily dose of <800 mg. The majority of
patients were treated for >4 weeks (75%). However,
treatment duration data based on interim analyses
are preliminary, as data will also reflect the point at
which patients started the study relative to the tim-
ing of database cut-off.
Sorafenib administration by region
Based on these preliminary findings, regional varia-
tion in dosing was observed. In Asia-Pacific, 66% of
patients received sorafenib for >4 weeks compared
with 77–97% of patients in other regions. Therefore,
patients in Asia-Pacific tended to stop sorafenib ther-
apy earlier than patients in other regions. The lowest
median daily dose was given in Japan (521 mg) and
the USA (564 mg). Patients in Asia-Pacific, Europe
and Latin America tended to receive a much higher
median daily dose (710–800 mg).
Sorafenib administration by physician specialty
Variations in sorafenib dosing patterns were seen
across physician specialties (Table 3). A greater per-
centage of Hep ⁄GIs initiated sorafenib therapy at
800 mg ⁄day compared with Med Oncs (83% and
65%, respectively), and Hep ⁄GIs gave a higher
Table 2 Disease characteristics
Total
(n = 479)
Geographic regions Specialty
Asia-Pacific
(n = 167)
Europe
(n = 143)
USA
(n = 116)
Latin America
(n = 32)
Japan
(n = 21)
Hep ⁄GI
(n = 248)
Med Onc
(n = 168)
BCLC staging*,, n (%)
Stage A 47 (10) 1 (1) 20 (14) 17 (15) 8 (25) 1 (5) 21 (8) 20 (12)
Stage B 92 (19) 19 (11) 32 (22) 21 (18) 11 (34) 9 (43) 55 (22) 25 (15)
Stage C 253 (53) 123 (74) 73 (51) 43 (37) 9 (28) 5 (24) 129 (52) 98 (58)
Stage D 29 (6) 7 (4) 7 (5) 11 (9) 3 (9) 1 (5) 17 (7) 10 (6)
TNM stage*,, n (%)
Stage I 31 (6) 2 (1) 10 (7) 14 (12) 5 (16) 0 15 (6) 8 (5)
Stage II 69 (14) 13 (8) 17 (12) 18 (16) 11 (34) 10 (48) 41 (17) 16 (10)
Stage IIIa 121 (25) 44 (26) 39 (27) 30 (26) 7 (22) 1 (5) 69 (28) 37 (22)
Stage IIIb 15 (3) 3 (2) 4 (3) 7 (6) 0 1 (5) 8 (3) 7 (4)
Stage IIIc 40 (8) 14 (8) 16 (11) 8 (7) 2 (6) 0 20 (8) 15 (9)
Stage IV 167 (35) 83 (50) 40 (28) 31 (27) 4 (13) 9 (43) 69 (28) 78 (46)
Extrahepatic spread*, n (%) 193 (40) 101 (60) 49 (34) 32 (28) 5 (16) 6 (29) 88 (35) 84 (50)
Child-Pugh status§, n (%)
A 278 (58) 101 (60) 100 (70) 47 (41) 14 (44) 16 (76) 149 (60) 91 (54)
B 134 (28) 44 (26) 30 (21) 41 (35) 15 (47) 4 (19) 80 (32) 34 (20)
C 11 (2) 1 (1) 2 (1) 8 (7) 0 0 5 (2) 5 (3)
CLIP score–, n (%)
0 30 (6) 5 (3) 11 (8) 7 (6) 6 (19) 1 (5) 16 (6) 10 (6)
1 93 (19) 19 (11) 39 (27) 19 (16) 7 (22) 9 (43) 53 (21) 26 (15)
2 99 (21) 30 (18) 33 (23) 20 (17) 8 (25) 8 (38) 60 (24) 23 (14)
3 75 (16) 27 (16) 20 (14) 22 (19) 4 (13) 2 (10) 48 (19) 20 (12)
4–6 68 (14) 34 (20) 15 (10) 15 (13) 3 (9) 1 (5) 46 (19) 16 (10)
Aetiology of underlying liver disease**, n (%)
Hepatitis B 194 (41) 140 (84) 25 (17) 23 (20) 1 (3) 5 (24) 89 (36) 77 (46)
Hepatitis C 146 (30) 12 (7) 47 (33) 58 (50) 17 (53) 12 (57) 82 (33) 44 (26)
Alcohol 138 (29) 29 (17) 60 (42) 40 (34) 5 (16) 4 (19) 84 (34) 42 (25)
Liver cirrhosis, n (%)
Yes 327 (68) 111 (66) 104 (73) 78 (67) 20 (63) 14 (67) 197 (79) 86 (51)
No 107 (22) 42 (25) 27 (19) 25 (22) 10 (31) 3 (14) 34 (14) 62 (37)
*Recorded at study entry (which is defined as start of therapy and is indicated by the initial visit); Data missing for six patients and not evaluable for 52 patients;
Data missing for six patients and not evaluable for 30 patients; §Data missing for five patients and not evaluable for 51 patients; –Data missing for seven patients
and not evaluable for 107 patients; **Patients could have >1 underlying liver disease; other aetiologies included non-alcoholic steatohepatitis, metabolic factors and
haematochromatosis; Data missing for one patient and unknown for 47 patients; Includes clinical, histologic or radiologic diagnosis.
BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program; TNM, tumour, node, metastasis.
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median daily dose than Med Oncs (774 mg and
570 mg, respectively).
Sorafenib administration by Child-Pugh status
Sorafenib administration based on Child-Pugh classi-
fication was also assessed (Table 3). Duration of
treatment was generally shorter in Child-Pugh A
than in Child-Pugh B patients. A greater number of
Child-Pugh A patients received treatment for
>8 weeks compared with Child-Pugh B patients
(65% vs. 42%). These preliminary data suggest that
patients with advanced Child-Pugh status tended to
stop sorafenib treatment earlier than patients with
less advanced disease. However, a number of Child-
Pugh B patients were treated for longer periods, and
7% and 10% of Child-Pugh B and Child-Pugh A
patients, respectively, received >28 weeks of sorafenib
therapy.
Child-Pugh score did not seem to influence the
starting dose of sorafenib, and at least 75% of
patients in both Child-Pugh A and Child-Pugh B
groups received the recommended initial daily dose
of 800 mg sorafenib (79% and 75%, respectively).
Overall, the dosing strategy for Child-Pugh B
patients did not appear to be different from that for
Child-Pugh A patients.
Safety assessments
Safety data from this first interim analysis are preli-
minary; however, the overall safety profile of sorafenib
in this first interim analysis was consistent with that
reported in previous clinical studies and no unforeseen
AEs were reported (Tables 4 and 5). A total of 87% of
patients reported at least one AE. Drug-related AEs
were experienced by 319 patients (67%): 41% with
grade 1 or 2 events and 25% with grade 3 or 4 events.
Overall, 42% of patients (n = 201) experienced SAEs
and 11% experienced drug-related SAEs. Study drug
was permanently discontinued as a result of AEs in
28% of patients. This was because of a variety of AEs,
each with a relatively low incidence in the overall pop-
ulation. The most commonly reported AEs in the
overall population included diarrhoea, hand-foot skin
reaction, fatigue, rash ⁄desquamation and anorexia
(Table 5). Hand-foot skin reaction and fatigue were
the most commonly reported grade 3 or 4 AEs within
the study population.
AE profiles were comparable between subgroups of
Child-Pugh status (Table 4). The overall incidence of
treatment-emergent AEs was slightly higher in Child-
Pugh B patients than in Child-Pugh A patients (91%
vs. 84%, respectively); however, the incidence of
drug-related AEs was similar in both Child-Pugh A
Table 3 Summary of sorafenib administration stratified by region, specialty and Child-Pugh status
Sorafenib
administration
Total
(n = 479)
Geographic regions Specialty Child-Pugh status*,
Asia-Pacific
(n = 167)
Europe
(n = 143)
USA
(n = 116)
Latin
America
(n = 32)
Japan
(n = 21)
Hep ⁄GI
(n = 248)
Med Onc
(n = 168)
Child-Pugh A
(n = 278)
Child-Pugh B
(n = 134)
Duration of treatment, n (%),§
£4 weeks 106 (22) 50 (30) 25 (17) 26 (22) 1 (3) 4 (19) 53 (21) 40 (24) 47 (17) 44 (33)
>4–8 weeks 87 (18) 32 (19) 23 (16) 22 (19) 5 (16) 5 (24) 44 (18) 28 (17) 45 (16) 29 (22)
>8–12 weeks 72 (15) 24 (14) 20 (14) 22 (19) 3 (9) 3 (14) 32 (13) 32 (19) 38 (14) 19 (14)
>12–16 weeks 53 (11) 14 (8) 19 (13) 10 (9) 5 (16) 5 (24) 35 (14) 15 (9) 34 (12) 10 (7)
>16–20 weeks 56 (12) 11 (7) 26 (18) 10 (9) 5 (16) 4 (19) 22 (9) 22 (13) 44 (16) 7 (5)
>20–24 weeks 30 (6) 9 (5) 8 (6) 9 (8) 4 (13) 0 16 (6) 12 (7) 20 (7) 8 (6)
>24–28 weeks 25 (5) 11 (7) 7 (5) 6 (5) 1 (3) 0 13 (5) 9 (5) 18 (6) 2 (1)
>28 weeks 38 (8) 10 (6) 10 (7) 10 (9) 8 (25) 0 24 (10) 7 (4) 27 (10) 10 (7)
Median daily
dose–,**, mg
692 710 779 564 800 521 774 570 624 800
Initial dose of
800 mg ⁄ day, n (%)
363 (76) 133 (80) 114 (80) 69 (59) 31 (97) 16 (76) 206 (83) 109 (65) 221 (79) 100 (75)
Permanent
discontinuation of
sorafenib because
of AEs, n (%)
133 (28) 49 (29) 36 (25) 37 (32) 2 (6) 9 (43) 81 (33) 34 (20) 69 (25) 53 (40)
*At start of therapy; Data missing for five patients and not evaluable for 51 patients; Time in weeks from initial visit to last dosing date (for ongoing patients to
last visit date) +1; §Data missing for 12 patients; –Determined per patient based on actual days on study drug (interruptions excluded); **Based on 367 patients; 
114 patients received £ 600 mg ⁄ day and data missing for two patients.
AE, adverse event; GI, gastroenterologist; Hep, hepatologist; Med Onc, medical oncologist.
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and B patients (69% vs. 63%, respectively). The
incidence of grade 3 or 4 drug-related events was
consistent, with 23–24% of grade 3 and 3–4% of
grade 4 events experienced by patients in each of the
Child-Pugh A and B subgroups. Drug-related SAEs
occurred in 10% of Child-Pugh A and 16% of
Child-Pugh B patients. The rate of discontinuation
of sorafenib because of AEs, regardless of any causal
relationship with sorafenib, was higher in patients
with Child-Pugh B status (40%) than in patients
with Child-Pugh A status (25%). The safety profile
of Child-Pugh B patients was generally consistent
with the overall safety profile.
Discussion
The GIDEON study is, to date, the largest, prospec-
tive, non-interventional global study to investigate
the treatment of patients with uHCC in the real
world and reflects participating physicians’ current
practice. Data have been collected from a wide
uHCC population, and the study database allows
analyses of global and regional differences in patient
characteristics, disease aetiology, underlying liver dis-
orders and practice patterns.
Demographic data for patients in the first interim
analysis of this study were consistent with findings
from previously reported epidemiological HCC stud-
ies (14,15). The first interim analyses of the GIDEON
study highlight notable regional differences in patient
and disease characteristics, aetiology and risk factors
of uHCC. Global variations in the aetiology of HCC,
in particular HBV and HCV, have been previously
reported (2,16). TACE is the current standard of care
for patients with multinodular, intermediate-stage
uHCC (13,17) and this is reflected in the patterns of
TACE used in this first interim analysis. Interestingly,
Table 4 Treatment-emergent adverse events by Child-Pugh status
Treatment-emergent
adverse events, n (%) Total (n = 479)
Child-Pugh status at start of therapy
Child-Pugh A (<7)
(n = 278)
Child-Pugh B (7–9)
(n = 134)
Child-Pugh C (>9)
(n = 11)
AEs (all grades) 415 (87) 234 (84) 122 (91) 10 (91)
AEs (grade 3 or 4) 194 (41) ⁄ 43 (9) 98 (35) ⁄ 19 (7) 70 (52) ⁄ 20 (15) 4 (36) ⁄ 2 (18)
Drug-related AEs (all grades) 319 (67) 193 (69) 84 (63) 6 (55)
Drug-related AEs (grade 3 or 4) 110 (23) ⁄ 12 (3) 66 (24) ⁄ 7 (3) 31 (23) ⁄ 5 (4) 3 (27) ⁄ 0
SAEs* (all grades) 201 (42) 93 (33) 80 (60) 7 (64)
Drug-related SAEs* (all grades) 51 (11) 28 (10) 22 (16) 0
AEs resulting in permanent
discontinuation of sorafenib
133 (28) 69 (25) 53 (40) 5 (45)
Deaths 114 (24) 49 (18) 50 (37) 4 (36)
*An SAE is defined as any AE occurring at any dose that results in any of the following outcomes: death; life-threatening; hospitalisa-
tion or prolongation of existing hospitalisation; persistent or significant disability ⁄ incapacity; congenital anomaly ⁄ birth defect; medically
important event; Any AE; Deaths while on treatment and up to 30 days after last dose of study drug.
AE, adverse event; SAE, serious adverse event.
Table 5 Treatment-emergent adverse events in ‡5% of
the total study population
n (%)
Treatment-
emergent
adverse events
(n = 479)
Treatment-
emergent
drug-related
adverse events
(n = 479)
All
grades
Grade
3 or 4
All
grades
Grade
3 or 4
Any adverse
event
415 (87) 161 (34) 319 (67) 109 (23)
Diarrhoea 132 (28) 10 (2) 114 (24) 8 (2)
Hand-foot
skin reaction
126 (26) 26 (5) 124 (26) 26 (5)
Fatigue 81 (17) 27 (6) 51 (11) 16 (3)
Rash ⁄
desquamation
73 (15) 12 (3) 63 (13) 12 (3)
Anorexia 55 (11) 24 (5) 39 (8) 7 (1)
Abdominal pain 53 (11) 20 (4) - -
Liver dysfunction 42 (9) 11 (2) - -
Nausea 41 (9) 5 (1) 25 (5) 4 (1)
Ascites 39 (8) 24 (5) - -
Hyperbilirubinemia 38 (8) 22 (5) - -
Hypertension 36 (8) 12 (3) 29 (6) 9 (2)
Alopecia 29 (6) 0 28 (6) 0
Vomiting 29 (6) 3 (1) - -
Weight loss 28 (6) 4 (1) - -
Fever 25 (5) 2 (<1) - -
Encephalopathy 25 (5) 10 (2) - -
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regional variations are observed with patients in
Japan and Asia-Pacific receiving more prior TACE
than in other regions. This is the first time that vari-
ations in the management of uHCC in real-life prac-
tice have been evaluated in a single robust study
with consistent methodology.
In this interim analysis, dosing differences based on
non-clinical factors such as region and specialty are
observed; however, Child-Pugh status does not appear
to be a factor for sorafenib dosing patterns. The so-
rafenib dosing findings in this study are preliminary.
Sorafenib dosing will continue to be evaluated in the
GIDEON study, with the aim of optimising sorafenib
treatment. It will be important to further explore rea-
sons for these differences in sorafenib usage (between
Med Oncs and Hep ⁄GIs, and across regions).
The safety profile reported in this first interim
analysis is consistent with that previously published
from randomised clinical trials, with no unexpected
AEs (9,10). The most commonly reported drug-
related AEs reflect the findings of previous clinical
studies of sorafenib in patients with uHCC. In the
SHARP and Asia-Pacific studies, diarrhoea, fatigue
and hand-foot skin reactions were also the most
commonly reported drug-related AEs (9,10).
The safety profile observed in the GIDEON first
interim analysis is generally similar in both Child-
Pugh A and B patients. Overall, Child-Pugh B score
does not appear to be associated with an increased
incidence of drug-related AEs, compared with Child-
Pugh A. These interim safety results support pub-
lished data from clinical studies of patients with
HCC on the safety of sorafenib in Child-Pugh B
patients, in which there was no major difference in
the incidence ⁄ grade of AEs between Child-Pugh A
and B patients (11,18–20).
The results from this first interim analysis are preli-
minary and should be interpreted accordingly. Obser-
vational studies have their limitations, principally in
the lack of a control arm and randomised study popu-
lation; nonetheless, results from the GIDEON study
provide the opportunity to evaluate a wide range of
data in uHCC patients and sorafenib use globally. Ini-
tial findings provide an interesting insight into real-life
clinical practice. The study is ongoing with final analy-
ses planned 12 months after enrolment of the 3000th
treated patient (12). Future reports will provide further
evidence that may help inform treatment choices and
contribute to the advancement of HCC management.
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